1. Use of nDx 1 Software is only available to partners who are registered separately in Novomics.
2. You must pass the certification procedure on the next screen before you can use the software.
3. Click the "Certification" button to install it automatically on your connection PC.
* Contact us : +82-2-2068-3700
The prognosis result with the classification of risk parameters (Low risk, Intermediate risk, and High risk) can be used as supplementary information to identify a treatment method in gastric cancer by clinicians.
|1||Information of patient, physician, hospital and specimen|
|3||Interpretation of risk parameter’s 5-year overall survival within the 95% confidence interval|
|4||5-year overall survival was 81.98% (95% CI 74.12 ~ 90.67%) in low risk, 66.18% (95% CI 60.58 ~ 72.30%) in intermediate risk, and 55.74% (95% CI 50.52 ~ 61.49%) in high risk.|
This section provides prognostic classification of the nProfiler® 1 Stomach Cancer Assay, including the results of analytical performance and clinical performance, and risk parameters by algorithm. nProfiler® 1 measures gene-expression levels in FFPE tumor cancer tissue samples and then classify the post-operative prognosis using algorithm. The assay analysis results in patient stratification according to the assigned risk parameters (Low risk, Intermediate risk, and High risk) to identify a patient’s survival likelihood for the next 5 years. Clinically, the assay provides clinicians with auxiliary information distinct from the standard risk-stratification methods, which might be useful when making decisions about adjuvant therapy.
|1||Visual Representation of Quantitative Single Gene Value
This section delivers quantitative single gene values of four classifier genes (GZMB, WARS, SFRP4, and CDX1) for a patient sample with threshold value on the bar graph, indicating binary position and figures.
|2||Four Classifier Gene Information about Biological Characteristics
This section provides four-gene information related to relevant gastric cancer features (GZMB, WARS, SFRP4, and CDX1).